Prescription Drugs: Global Outlook to 2008

1.Disease Demographics and the Rx Drug Market
   Pharmaceutical Planning and Disease Statistics 
   The Scale of Major Disease Populations
  Health Risks and Death Linked to `Modern' Lifestyle
2.Leading Rx Drugs, Revenues and Drug Companies
   The Leading Twenty Prescription Drugs
     Leading Twenty Rx Drugs by Disease Categories
     Leading Twenty Rx Drugs by Top Pharma Companies
   The Best Selling 276 Prescription Drugs
     The Best Selling Drugs by Disease Categories
3.Drug Market Distribution, Price and Cost Arrangement
   Approaches to Regional Price Setting
   A Case Study of a Drug Distribution Channel
     Distribution Supply Chain and Distributors 
     Example of How Rx Drugs Reach Patients (HMO)
4.Pharma Partnering and M&A Trends
   Review of Pharmaceutical Partnerships
   Comparing Alliances and M&As
   Key Findings About Alliances and M&As
   Background to the Following Data Tables
5.Patent Expiries and New Drug Pipelines 
   The Impact of Nearing Patent Expirations 
   Late Stage Drug Pipeline in 2003
6.Navigating World Drug Regulatory Organizations Drug
   R&D and Regulatory Approval Processes 
     Drug Approvals in the USA (North America)
     Overview of the Drug Approval Process in the 
     USA (FDA)
   Drug Approvals in the European Union (EU)
     Overview of the Drug Approval Process in the 
     European Union
     `Mutual Recognition' Principle
     The Centralized Approval Procedure
     Decentralized Approval Procedure
   Drug Approvals in Japan
     Overview of the Drug Approval Process in Japan
     Applications for Approval of Drugs Manufactured
     Outside of Japan
     Japan's Priority Review System 
     The Orphan Drug Designation
  Regional Drug Regulatory Issues to Consider
     USA (North America)
     The European Union
     In Japan
7.The Global Rx Drug Market Size and Outlook to 2008
   Rx Drug Market Size of the Developed World
   Selected Top 276) Global Rx Drug Market Size by
   Disease and Revenues
   Top Six Market Segments and Subsegments
8.Conclusions and Issues to Consider
   Drug Companies Use Disease Demographics
     Epidemiology Based Pharmaceutical Planning Large
     Disease Populations Point to Potential Marketing 
     Opportunities
     Health Risk Factors Lead to Sickness & Death 
   Key Points about Global Regulators and Issues
     Need for Government Drug Regulatory Approval
     International Drug R&D and Approval Processes
     Regulatory Trends
   Drug Patent Expiration Dates and New Drug
     Pipeline Patent Expirations Looming to
     Cause Big Losses Current Drug R&D
     Pipeline is Weak
   Drug Pricing & Distribution Arrangements
     Pricing Arrangements
     Drug Distribution Supply Chain
   Pharma Alliances and M&As
     Alliance Trends
   Rx Drug Market Size 
   Best Selling Rx Drugs 
   Issues to Consider
9.Appendix
   Pharmaceutical Business Glossary 
   Contacts to the Top 55 Pharma Companies
   Links to Worldwide Drug Regulatory Organizations

List of Tables

Table 1. Major Disease Populations by Annual New Patients
Table 2. Major Disease Populations by Total Existing
         Patients
Table 3. Disease Populations in the Developed World
Table 4. Major Health Risk Factors Leading to Death
Table 5. Leading 20 Rx Drugs Global Sales ($M)
Table 6. Leading 15 Disease Categories by Global Sales
Table 7. Disease Category Definitions Used in this Section
Table 8. Rx Drugs by Disease Indication and Global Sales
Table 9. Rx Drug Pricing Tiers and Channels by Region
Table 9. Rx Drug Pricing Tiers and Channels by Region
Table 10. Model of US Pricing for Brand Name Rx Drugs 
Table 11. Top Level of US Wholesale Rx Drug Distribution
          Channel
Table 12. Details of the US Retail Pharmacy Channel
Table 13. Key Rx Drug Distributors by International Region
Table 14. Map of Pharma Alliances and M&As
Table 15. Pharma Strategic Alliances and M&As by Major
          Disease
Table 16. Alliances and M&As, 2003
Table 17. Alliances and M&As, 2002
Table 18. Alliances and M&As, 2001
Table 19. Alliances and M&As, 2000
Table 20. Summary of Drug Patent Expirations and Lost
          Revenues
Table 21. Drug Patent Expirations to 2008
Table 22. Drug Patent Expirations by Disease Category and
          Indication
Table 23. Drug Pipeline by Clinical Phase in 2003
Table 24. Drug Pipeline Summary by Disease for 2003
Table 25. Late Stage Rx Drug Development Pipeline (2003)
Table 26. Relationship of Drug Regulation to Drug
          Development
Table 27. Total Audited World Rx Drug Sales by Regions,
          2002
Table 28. Estimated Global Rx Drug Sales by Regions, 2002-
          2008E
Table 29. Top 10 Products in 2002 Global Rx Drug Sales
Table 30. Top 276 Human Rx Drug Global Market Size Sorted
          by 2003 Revenues ($M) and Disease Segments
          (Summary), 2002-2008E
Table 31. Top 276 Human Rx Drug Global Market Size Sorted
           by CAGR and Disease Segments (Summary), 2002-2008E 
Table 32. Top 276 Human Rx Drug Global Market Size by
           Disease (Detail) ($M) 2002-2008E

List of Illustrations

Figure 1. An Rx Drug Distribution Arrangement
Figure 2. Map of Strategic Alliances and M&As
Figure 3. Selected M&As by Valuation ($M)
Figure 4. Pharma Strategic Alliances and M&As by Major
          Disease
Figure 5. Navigating the Drug R&D and Approval Process
Figure 6. The US FDA New Drug Approval Process Flowchart
Figure 7. EU Centralized Drug Approval Procedure Flowchart
Figure 8. EU Decentralized New Drug Approval Procedure
          Flowchart
Figure 9. Japan MHLW New Drug Approval Flowchart
Figure 10. Estimated Selected (Top 276) Human Rx Drug Global
           Market Size by Revenues ($M) and Disease Segments,
           2002-2008E
Figure 11. Comparison of Disease Segment Market Shares for
           the Selected (Top 276) Global Human Rx Drug Market,
           2002 and 2008
Figure 12. Market Size by the Estimated `Cardiovascular'
           Segment Revenues, 2002-2008
Figure 13. Market Size by Estimated `CNS' Subsegment
           Revenues, 2002-2008
Figure 14. Market Size by Estimated `Infections' Subsegment
           Revenues, 2002-2008
Figure 15. Market Size by Estimated `Respiratory & Allergy'
           Subsegment Revenues, 2002-2008
Figure 16. Market Size by the Estimated `Gastrointestinal'
           Subsegment Revenues, 2002-2008
Figure 17. Market Size by the Estimated `Cancer' Subsegment
           Revenues, 2002-2008